With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with a transaction set to propel the company into the CDMO market.

Meanwhile, Jabil’s market share has declined slightly from 5.3% in 2027 to 4.9% in 2024. We noted that Jabil’s revenue in 2024 has experienced the highest decline among competitors ...

The manufacturer has been exploring a sale since 2023. STORY HIGHLIGHTS Jabil Inc. acquired Pharmaceutics International Inc. on Feb. 3. Pharmaceutics operates a 360,000-square-foot campus in Hunt ...

St. Petersburg electronics giant Jabil Inc. and Amazon are formalizing a partnership to strengthen ties between their cloud-related businesses. St. Petersburg electronics giant Jabil Inc. and ...

In this article, we are going to take a look at where Jabil Inc. (NYSE:JBL) stands against the other AI stocks. Artificial intelligence has become a dominant force in the stock market, driving the ...

Investors with a lot of money to spend have taken a bullish stance on Jabil JBL. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Jabil (JBL – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Ruplu Bhattacharya from Bank of America Securities reiterated a Buy rating on ...